Physician profile
Monisha Bindra
NPI 1467668483
$2,326.93
in general payments reported to CMS, 2019-2025
10 companies · $289 in 2025
The $289 reported for 2025 was more than what 88% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $347 · 2023: $737 · 2024: $954 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,979.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $685.57 | 2022-2024 | Xarelto |
| Inari Medical, INC. | $658.24 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbvie INC. | $520.72 | 2023-2025 | Dalvance |
| Csl Behring | $122.06 | 2022 | |
| Fisher & Paykel Healthcare INC | $107.79 | 2023-2024 | Fisher & Paykel Healthcare |
| Astrazeneca Pharmaceuticals Lp | $89.01 | 2023-2024 | Andexxa |
| Pfizer INC. | $65.43 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $30.43 | 2023 | Soliris |
| Amgen INC. | $27.40 | 2025 | Uplizna |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monisha Bindra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.